[ad_1]
Lantern Pharma LTRN is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here’s what investors need to know before the announcement.
Analysts estimate that Lantern Pharma will report an earnings per share (EPS) of $-0.54.
Lantern Pharma bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
Last quarter the company beat EPS by $0.11, which was followed by a 0.71% drop in the share price the next day.
Here’s a look at Lantern Pharma’s past performance and the resulting price change:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.52 | -0.29 | -0.40 | -0.27 |
| EPS Actual | -0.41 | -0.38 | -0.31 | -0.36 |
| Price Change % | -0.71% | 2.15% | 4.43% | -0.99% |
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.52 | -0.29 | -0.40 | -0.27 |
| EPS Actual | -0.41 | -0.38 | -0.31 | -0.36 |
| Price Change % | -0.71% | 2.15% | 4.43% | -0.99% |
Stock Performance
Shares of Lantern Pharma were trading at $4.43 as of November 03. Over the last 52-week period, shares are down 56.96%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Lantern Pharma visit their earnings calendar on our site.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.